• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, January 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Safety evaluation of conditionally immortalized cells for renal replacement therapy

Bioengineer by Bioengineer
November 25, 2019
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Here, the research team assessed the safety of conditionally immortalized proximal tubule epithelial cells for bioartificial kidney application, by using in vitro assays and athymic nude rats

IMAGE

Credit: Correspondence to: Rosalinde Masereeuw, email: [email protected]


Here, the research team assessed the safety of conditionally immortalized proximal tubule epithelial cells for bioartificial kidney application, by using in vitro assays and athymic nude rats.

They demonstrate that these cells do not possess key properties of oncogenically transformed cells, including anchorage-independent growth, lack of contact inhibition and apoptosis-resistance.

Taken together, this study lays an important foundation towards bioartificial kidney development by confirming the safety of the cell line intended for incorporation.

Dr. Rosalinde Masereeuw from the Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands said, “End-stage kidney disease represents irreversible kidney failure through a variety of causes.”

Human primary proximal tubule epithelial cells have a limited life span in vitro and presenting risks, such as functional changes occurring upon culturing as well as dedifferentiation and senescence of cells.

Issues related to the use of animal-derived cells in BAK are safety concerns compromising approval for clinical application and species differences in cell behaviour.

Due to the expression of temperature-sensitive SV40T, cells can be expanded at permissive temperature of 33 C and differentiated into mature cells at non-permissive temperature of 37 C.

With this cell line the authors demonstrated the capacity of an efficient removal of uremic toxins when cells are cultured on hollow fiber membranes , thereby creating fully functional kidney tubules.

Finally, they evaluated cell transforming properties and tumorigenic potential in vivo to gain more insight into safety and suitability of these cells for applications in renal replacement therapies.

The Masereeuw Research team concluded, “by showing that ci PTEC-OAT1 do not portray fundamental characteristics of oncogenically transformed cells, do not present negative consequences of viral transductions and genomic transgene integrations, such as insertional mutagenesis, nor possess tumorigenic capacity in vivo, the present study lays an important foundation towards validating the safety of a conditionally immortalized cell line for clinical application as cell-based renal replacement therapy.”

###

Full text – http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=27152&path%5B%5D=86951

Correspondence to – Rosalinde Masereeuw – [email protected]

Keywords – bioartificial kidney, cell therapy safety, conditionally immortalized proximal tubule epithelial cells, tumorigenicity, viral integration

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open-access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit http://www.oncotarget.com or connect with @OncotargetJrnl

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957×105

[email protected]

Media Contact
Ryan James Jessup
[email protected]
800-922-0957 x105

Original Source

http://www.oncotarget.com/news/pr/safety-evaluation-of-conditionally-immortalized-cells-for-renal-replacement-therapy

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27152

Tags: cancerMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Revolutionary Support Program for Families of Cancer Patients

January 16, 2026

Spatial Multiomics Uncovers Immune Dysfunction in Parkinson’s, IBD

January 16, 2026

Psychiatric Nurses’ Views on AI in Care

January 16, 2026

Korean Medicine’s Approach to Herpes Zoster Management

January 16, 2026
Please login to join discussion

POPULAR NEWS

  • Enhancing Spiritual Care Education in Nursing Programs

    155 shares
    Share 62 Tweet 39
  • PTSD, Depression, Anxiety in Childhood Cancer Survivors, Parents

    147 shares
    Share 59 Tweet 37
  • Robotic Ureteral Reconstruction: A Novel Approach

    76 shares
    Share 30 Tweet 19
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Carbon Fiber Boosts Zirconium Diboride in 3D Printing

Revolutionary Support Program for Families of Cancer Patients

Spatial Multiomics Uncovers Immune Dysfunction in Parkinson’s, IBD

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 71 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.